摘要
目的:探讨血管增殖与腋窝淋巴结阳性的乳腺癌患者接受蒽环类药物辅助化疗的相关性。方法:采用免疫组织化学的方法(LSAB法)检测接受过蒽环类药物化疗的78例淋巴结阳性的乳腺癌标本中CD31的表达,并结合微血管计数和随访结果,用χ2检验、单因素和多因素分析进行统计学处理。结果:微血管计数水平较高的患者5年生存率为65.39%,明显低于微血管计数水平低的患者(85.52%,P=0.0066);肿瘤组织中高水平的血管增殖与患者无瘤生存率(P=0.0034)和总生存率(P=0.007)有很强的相关性。结论:肿瘤组织内血管增殖水平的高低在淋巴结阳性的乳腺癌患者中是一个独立的预后指标;高水平血管增殖的存在不仅预示着患者可能在短期内复发或转移,同时提示对蒽环类药物存在抵抗性,这可能是这类患者预后较差的一个重要原因。
Objective:To evaluate the relationship between angiogenesis and node-positive breast cancer patients receiving anthracycline-based adjuvant chemotherapy.Methods:Seventy-eight node-positive breast cancer patients who received anthracycline-based adjuvant chemotherapy were selected.Angiogenesis was evaluated using CD 31 antibody.The results of microvessel count and follow-up were treated by using X 2 test,univariate and multivariate analysis.Results:The5-year survival rate was68.76%if the tumors had high MVC as compared with88.13%for those with low MVC.A high level of tumoral angiogenesis was strongly correlated with metasta sis-free survival(P=0.0034)and overall survival(P=0.007).Conclusion:A relative chemoresis tance of tu mors with high levels of tumor angiogenesis could explain their worse prognosis.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2002年第4期268-272,共5页
Chinese Journal of Clinical Oncology
